CD45RC expression is not altered before and after HSCT. (A) Expression level of CD45RC was analyzed on human T cells from PBMCs from healthy individuals or 88 patients between 15 and 65 years of age with de novo or secondary acute myeloid leukemia (AML) before (pregraft [PG]) hematopoietic stem cell transplantation (HSCT) or at month 3 (M3) and month 24 (M24) after HSCT. Mean expression ± SEM of CD45RC^high, CD45RC^low, CD45RC⁻ at the different times analyzed. (B) Representative staining is shown. Cells were first gated on morphology, singlet cells, live cells, and CD3⁺ cells. FMO, Fluorescence Minus One control; FSC-A, forward scatter area; FSC-H, FSC height; SSC-A, side scatter area; SSC-H, SSC height.